United Therapeutics Corporation Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment
United Therapeutics Corporation (UTHR) reported Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment of $3.80 million for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-02.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfTradingSecuritiesHeldforinvestment · last filed 2022-11-02
- United Therapeutics Corporation proceeds from sale of debt and equity securities, fv-ni, held-for-investment for the quarter ending 2022-09-30 was $3.80M.
- United Therapeutics Corporation proceeds from sale of debt and equity securities, fv-ni, held-for-investment for the quarter ending 2022-06-30 was $0.00.
- United Therapeutics Corporation proceeds from sale of debt and equity securities, fv-ni, held-for-investment for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- United Therapeutics Corporation proceeds from sale of debt and equity securities, fv-ni, held-for-investment for the quarter ending 2021-12-31 was $2.60M.
- United Therapeutics Corporation proceeds from sale of debt and equity securities, fv-ni, held-for-investment for fiscal 2021 was $111.50M, a 308.42% increase from fiscal 2020.
- United Therapeutics Corporation proceeds from sale of debt and equity securities, fv-ni, held-for-investment for fiscal 2020 was $27.30M, a 33.17% increase from fiscal 2019.
- United Therapeutics Corporation proceeds from sale of debt and equity securities, fv-ni, held-for-investment for fiscal 2019 was $20.50M.
- United Therapeutics Corporation proceeds from sale of debt and equity securities, fv-ni, held-for-investment for fiscal 2018 was $0.00.
| Period end | Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment 3 month | Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment 6 month | Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment 9 month | Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment 12 month |
|---|---|---|---|---|
| 2022-09-30 | $3.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $3.80M derived: sum of 2 quarters · filed 2022-11-02 | $3.80M 10-Q · filed 2022-11-02 | $6.40M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $0.00 10-Q · filed 2022-08-03 | $2.60M derived: sum of 3 quarters · filed 2022-08-03 | $2.60M derived: sum of 4 quarters · filed 2022-11-02 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-04 | $2.60M derived: sum of 2 quarters · filed 2022-05-04 | $2.60M derived: sum of 3 quarters · filed 2022-11-02 | $2.60M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $2.60M derived: sum of 2 quarters · filed 2022-11-02 | $2.60M derived: sum of 3 quarters · filed 2022-11-02 | $111.50M 10-K · filed 2022-02-24 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $0.00 derived: sum of 2 quarters · filed 2022-11-02 | $108.90M 10-Q · filed 2022-11-02 | $108.90M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $108.90M 10-Q · filed 2022-08-03 | $108.90M derived: sum of 3 quarters · filed 2022-11-02 | $122.00M derived: sum of 4 quarters · filed 2022-11-02 |
| 2021-03-31 | $108.90M 10-Q · filed 2022-11-02 | $108.90M derived: sum of 2 quarters · filed 2022-11-02 | $122.00M derived: sum of 3 quarters · filed 2022-11-02 | $123.00M derived: sum of 4 quarters · filed 2022-11-02 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $13.10M derived: sum of 2 quarters · filed 2022-02-24 | $14.10M derived: sum of 3 quarters · filed 2022-02-24 | $27.30M 10-K · filed 2022-02-24 |
| 2020-09-30 | $13.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $14.10M derived: sum of 2 quarters · filed 2021-11-03 | $27.30M 10-Q · filed 2021-11-03 | $47.80M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $14.20M 10-Q · filed 2021-08-04 | $34.70M derived: sum of 3 quarters · filed 2022-02-24 | $34.70M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $13.20M 10-Q · filed 2021-05-05 | $33.70M derived: sum of 2 quarters · filed 2022-02-24 | $33.70M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $20.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $20.50M derived: sum of 2 quarters · filed 2022-02-24 | $20.50M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $0.00 10-Q · filed 2020-10-28 | ||
| 2019-06-30 | $0.00 10-Q · filed 2020-07-29 | |||
| 2018-12-31 | $0.00 10-K · filed 2021-02-24 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $19.02M derived: sum of 2 quarters · filed 2012-02-28 | $36.20M 10-K · filed 2012-02-28 | |
| 2010-09-30 | $19.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $36.20M 10-Q · filed 2011-10-27 | ||
| 2010-06-30 | $17.18M 10-Q · filed 2011-07-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |